期刊
JOURNAL OF PEDIATRICS
卷 185, 期 -, 页码 112-+出版社
MOSBY-ELSEVIER
DOI: 10.1016/j.jpeds.2017.03.025
关键词
-
类别
资金
- National Heart, Lung, and Blood Institute [HL69413, K24 HL074864]
- Rady Children's Hospital San Diego Physician Development Fund
- National Center for Research Resources/National Center for Advancing Translational Sciences [UL1 TR001414]
- Macklin Foundation
Objectives To characterize the clinical presentation and outcome in infants <6 months of age with Kawasaki disease (KD) and to describe the use of newer anti-inflammatory therapies in this young population. Study design We evaluated 88 infants <6 months old and 632 >= 6 months old treated for KD. We compared differences in laboratory data, response to treatment, and coronary artery outcomes between the 2 cohorts. Fisher exact test was used to analyze categorical variables, whereas the Wilcoxon rank sum test was used for continuous variables. Results The majority of children in both cohorts were diagnosed and treated within the first 10 days of illness (median illness day 6 in both cohorts). For patients treated within the first 10 days after fever onset, a larger proportion of infants <6 months old had a dilated or aneurysmal coronary artery on the initial echocardiogram compared with those >= 6 months old (43.4% vs 19.5%). Furthermore, 18.6% of infants <6 months old who had a normal echocardiogram at diagnosis, developed a dilated or aneurysmal coronary artery on a subsequent echocardiogram within 8 weeks of diagnosis. Twenty-eight infants <6 months old received a single dose of infliximab without any untoward effects. Conclusions Despite treatment in the first 10 days, infants <6 months old with acute KD are more likely to develop coronary artery abnormalities. Thus, the development of adjunctive therapies to reduce coronary artery damage should target this population.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据